The transaction supports Embecta’s plan to diversify by supplying drug delivery solutions to pharmaceutical partners.

Embecta closed its acquisition of Owen Mumford Holdings on Friday, shifting its focus from diabetes products to broader ...

Auto-injectors are pre-filled, single-use, self-contained drug delivery systems that allow the user to self-administer precise dosages of injectable medication quickly and easily, without the ...

Phillips-Medisize, in collaboration with its customer, Ascendis Pharma, was recently recognized with a third industry award for the Skytrofa Auto-Injector. The Red Dot Award recognizes the drug ...

Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed ...

Anaphylaxis is a serious, potentially life-threatening allergic reaction that can affect several organ systems in the body and may threaten breathing and blood circulation. The most common causes of ...

TOKYO--(BUSINESS WIRE)--SHL, the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices, announced today that SHL Marketing Director Steven Kaufman will ...

- Supply agreement supports Viridian’s development of potential first- and best-in-class subcutaneous therapies for treatment of thyroid eye disease (TED) - - Ypsomed brings strong track record of ...

An announcement from Embecta Corporation ( (EMBC)) is now available. On May 15, 2026, Embecta completed its acquisition of Owen Mumford Holdings Limited, following a March 19, 2026 purchase agreement ...

The Aidaptus ® disposable auto-injector platform, designed by Owen Mumford, will be jointly offered to global biopharma companies to support their drug development programs with engineering and ...